Life Technologies Announces Filing of Definitive Proxy Statement, Sets Special Meeting Date for August 21 to Vote On Thermo Fisher Acquisition
Life Technologies Corporation (NASDAQ: LIFE), a leading life sciences company, today announced that it has filed a definitive proxy statement with the U.S. Securities and Exchange Commission regarding Thermo Fisher Scientific Inc.'s (NYSE: TMO) pending acquisition of the Company and has set the date for a special meeting of stockholders to approve the transaction.
Life Technologies' special meeting of stockholders will be held on Wednesday, August 21, 2013, at 8:00 a.m. Pacific Time. The meeting will be held at Life Technologies' corporate headquarters at 5781 Van Allen Way, Carlsbad, California.
All stockholders of record of Life Technologies' common stock as of the close of business on July 18, 2013, will be entitled to vote their shares either in person or by proxy. Under the terms of the merger agreement, each outstanding share of Life Technologies common stock would be converted into the right to receive $76.00 in cash, subject to potential increase in certain circumstances if the merger does not close by January 14, 2014, as described in the definitive proxy statement.
The Life Technologies' Board of Directors unanimously recommends that stockholders vote "FOR" the adoption of the merger agreement. The transaction, which is expected to be completed early in 2014, remains subject to the satisfaction of the closing conditions set forth in the merger agreement, including adoption of the merger agreement by Life Technologies' stockholders at the special meeting.
About Life Technologies
Life Technologies Corporation (NASDAQ: LIFE) is a global biotechnology company that is committed to providing the most innovative products and services to leading customers in the fields of scientific research, genetic analysis and applied sciences. With a presence in more than 180 countries, the company's portfolio of 50,000 end-to-end solutions are secured by more than 5,000 patents and licenses that span the entire biological spectrum -- scientific exploration, molecular diagnostics, 21st century forensics, regenerative medicine and agricultural research. Life Technologies has approximately 10,000 employees and had sales of $3.8 billion in 2012. Visit us at our website: http://www.lifetechnologies.com.
(c) 2013 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.